# Phase 50 — Prospective Stress Signal Validation (Master Report)

**DIAGNOSTIC VALIDATION ONLY. No live strategy code, YAML, risk, position sizing, or portfolio weight modified. No filter, limit, or control deployed.**

---

## 1. Executive summary

Testing Phase 49's two surviving research leads under a genuinely prospective, lookahead-safe design (predictor from a fully-closed prior trading day *T-1*, outcome on the following day *T*, verified via an explicit audit column asserted `True` for 100% of 773 rows) produces a clean, informative **double null result**. **H1 (conditional JPY exposure)**: of the 6 volatility×concurrency cells, only 2 per period had adequate sample (≥20 days); their effect directions disagreed with each other in both the discovery and validation periods (one cell favored JPY-high, the other favored JPY-low) — no majority direction, no signal. **H2 (concurrency concentration)**: the full-population primary test showed a **positive** (not negative) discovery-period effect — concurrency-high days were directionally *better*, not worse, in discovery — and the direction flipped to negative in validation, the opposite of a stable relationship. **Both hypotheses classify D. REJECTED — NO CREDIBLE SIGNAL.** Per the phase's own decision tree, this triggers the explicit recommendation: **stop portfolio-control research for now, continue live observation, do not begin a new strategy search.** Phase 49's within-stress-population concurrency concentration finding is reconfirmed here as a secondary descriptive fact (the low-concurrency subset of worst-10% days totals -93.5R of the bucket's -290.4R) but, exactly as Phase 49 itself warned, it does not survive translation into a genuine prospective signal.

## 2. Phase 49 context

Phase 49 concluded C. MULTI-FACTOR STRESS MECHANISM and identified exactly two research leads: H1 (JPY exposure conditional on volatility+concurrency, which survived Phase 49's own same-day temporal validation) and H2 (concurrency concentration within the stress population, which explicitly did *not* survive Phase 49's marginal temporal validation). Phase 50 was designed specifically to subject both to a stricter, genuinely prospective test.

## 3. Research questions

Can either signal identify portfolio stress before it occurs, using only information available at that time, and does the relationship survive a genuinely unseen temporal validation period?

## 4. Preregistration

`reports/phase50_preregistration.md`, committed separately (`1d55b16`) before any result. No amendment required.

## 5. Data audit

`reports/phase50_data_audit.csv` — 773 T-1→T rows (one fewer than Phase 49's 774-day ledger, since the first day has no predecessor), JPY median threshold 100.0%* (see limitation §26), concurrency threshold 4 (reused from Phase 43/49), stress threshold at the 10th percentile of full-period daily R, minimum cell size 20.

## 6. Prediction-time definitions

`reports/phase50_prediction_time_audit.csv` — **100% of 773 rows pass the lookahead-safety check** (`T-1` date strictly precedes `T` date); zero rows excluded. By construction, no predictor field is ever sourced from the outcome day.

## 7. H1 discovery

`reports/phase50_h1_discovery.csv`. Of 6 volatility×concurrency cells, only 2 reach the 20-day minimum: `NORMAL`+concurrency≥4 (effect -0.508, JPY-high worse) and `HIGH`+concurrency≥4 (effect +1.041, JPY-high *better*) — directly conflicting directions, no majority.

## 8. H1 validation

`reports/phase50_h1_validation.csv`. Same 2 adequately-sampled cells: `NORMAL`+concurrency≥4 (-0.702, JPY-high worse) and `HIGH`+concurrency≥4 (+0.001, essentially flat) — again no consistent majority direction, and the `HIGH`-vol cell's discovery-period positive effect did not even replicate as negative.

## 9. H1 effect size

`reports/phase50_h1_effects.csv`. Pooled (unconditional) discovery effect +0.157 (95% CI wide, spans zero); pooled validation effect -0.219 (also spans zero). Cellwise majority-negative: False in both periods (2 of 2 adequately-sampled cells never agree in direction in either period).

## 10. H2 discovery

`reports/phase50_h2_discovery.csv`. Full-population primary test: concurrency-high mean `T_total_R` +0.192 vs. concurrency-low -0.006 — a **positive** effect (concurrency-high *better*), the opposite of H2's hypothesized direction, on an adequate sample (244 vs. 142 days).

## 11. H2 validation

`reports/phase50_h2_validation.csv`. Concurrency-high mean +0.328 vs. concurrency-low +0.464 — now a **negative** effect (concurrency-high worse) — the direction **flipped** between discovery and validation, precisely the instability pattern Part 16 of the task warned might occur.

## 12. H2 effect size

`reports/phase50_h2_effects.csv`. Primary full-population effects: discovery +0.198 (CI -0.216 to +0.612), validation -0.136 (CI -0.526 to +0.255) — both confidence intervals span zero in both periods. Secondary descriptive (not the primary test): within the worst-10%-day population, the T-1-concurrency<4 subset totals -93.5R of the bucket's -290.4R total — reconfirming Phase 49's within-stress-population concentration as a descriptive fact, unchanged by this phase's stricter test.

## 13. Temporal validation

`reports/phase50_temporal_validation.csv` — consolidated view of both hypotheses' discovery/validation directions, both showing disagreement between periods.

## 14. Walk-forward validation

`reports/phase50_walk_forward.csv` — 2-fold expanding-window check. H1: fold 1 discovery -0.126 → validation +0.122 (sign flip); fold 2 discovery +0.007 → validation -0.120 (near-zero to negative). H2: fold 1 discovery +0.019 → validation +0.330 (same sign, but both weak/inconsistent with the primary split); fold 2 discovery +0.119 → validation -0.122 (sign flip). **No fold configuration for either hypothesis shows a stable, repeated direction across all available windows.**

## 15. H1×H2 interaction

`reports/phase50_h1_h2_interaction.csv` — **EXPLORATORY only**, per the frozen scope. Discovery: JPY-high+concurrency-high vs. all-other, effect +0.318 (CI spans zero). Validation: effect -0.194 (CI spans zero, and sign-flipped from discovery). No evidence of a stable joint effect; not used to rescue either failed primary hypothesis, per the explicit rule.

## 16. Multiple-testing controls

`reports/phase50_multiple_testing.csv` — 12 H1 sub-tests (6 cells × 2 periods) and 2 H2 primary tests logged as PRIMARY PREREGISTERED; the worst-10%-subset descriptive statistic explicitly logged as SECONDARY DESCRIPTIVE; the interaction test explicitly logged as SECONDARY EXPLORATORY.

## 17. Robustness

`reports/phase50_robustness.csv`. Excluding the worst 1 and 5 days does not materially change either hypothesis's already-weak, direction-unstable effect. Splitting the validation period itself in two shows further instability (H1: -0.448 first-half vs. +0.003 second-half; H2: -0.122 vs. -0.142, at least directionally consistent within this specific sub-split, though this does not rescue H2's discovery-vs-validation sign flip already documented in §11).

## 18. Live comparison

`reports/phase50_live_comparison.csv` — **CONTEXTUAL ONLY, not validation**, per the explicit rule. The live post-demotion sample (19 trades) shows 89.5% JPY share, *below* the historical median (100.0%* — see §26 limitation) — descriptively unremarkable, and far too small to speak to either hypothesis regardless.

## 19. Phase 44 connection

Phase 44's NO PORTFOLIO CONTROL JUSTIFIED finding is not retested, re-optimized, or overturned. Since neither hypothesis reached A. VALIDATED, this phase does **not** state that evidence is now sufficient for a dedicated intervention-design phase — the opposite conclusion, per §20's decision matrix.

## 20. Decision matrix

`reports/phase50_decision_matrix.csv`:

| Hypothesis | Discovery direction | Validation direction | Classification |
|---|---|---|---|
| H1 (conditional JPY exposure) | positive/no signal | positive/no signal | **D. REJECTED — NO CREDIBLE SIGNAL** |
| H2 (concurrency concentration) | positive/no signal | negative | **D. REJECTED — NO CREDIBLE SIGNAL** |

## 21. What was validated

Nothing reached A. VALIDATED.

## 22. What was rejected

Both H1 and H2, at the D. REJECTED — NO CREDIBLE SIGNAL level — the strictest rejection tier, not merely "unconfirmed."

## 23. What remains uncertain

Whether a differently-specified conditional JPY signal (e.g., using a continuous rather than median-split JPY measure, or a different concurrency threshold) would fare better — explicitly **not tested**, per the no-threshold-mining rule; this remains a live, disclosed unknown rather than a swept-under-the-rug possibility.

## 24. Intervention implications

None. No portfolio control, filter, or risk change is justified by this phase's evidence.

## 25. Strategy-search implications

None — this phase does not bear on the FX-technical research ceiling question (Phase 39), which remains separately unchanged.

## 26. Limitations

- The JPY-share median-split threshold (100.0%) is unusually high because a large majority of trading days in this control have 100% JPY-linked trade activity (a restatement of the portfolio's known JPY concentration, Phase 31/41/45) — meaning the "JPY-low" group in several cells is thin even where the overall cell meets the 20-day floor, a genuine, disclosed sample-composition limitation not fully captured by the cell-level ADEQUATE/INSUFFICIENT flag alone.
- Only 2 of 6 preregistered H1 cells ever reach adequate sample in either period — the primary H1 test is materially underpowered relative to its original 6-cell design, disclosed rather than papered over.
- The interaction test (§15) and the validation-half-split robustness check (§17) both show internally inconsistent signs across sub-periods — consistent with, not contradicting, the primary D classification.
- This phase's stricter (T-1→T, 20-day floor) design is a materially different test from Phase 49's same-day, 10-day-floor design — the two phases' results are not directly comparable number-for-number, only directionally, and that difference in rigor is the entire point of this phase.

## 27. Phase 50 final verdict

### Answers to the 26 required questions

1. **Does conditional JPY exposure predict subsequent portfolio stress?** No — no consistent direction found.
2. **Survives volatility and concurrency control?** The conditioning was applied as designed; no stable relationship emerged within it.
3. **Survives chronological validation?** No.
4. **Economically meaningful?** Not established — no stable effect to size.
5. **Does pre-outcome concurrency predict subsequent stress?** No — direction flips between discovery and validation.
6. **Survives temporal validation?** No.
7. **Does either relationship reverse sign?** Yes — H2 reverses between discovery and validation; H1's two adequately-sampled cells disagree with each other in both periods.
8. **Does the JPY×concurrency interaction add information?** No stable pattern (exploratory only).
9. **Robust after excluding outliers?** The already-weak effects remain weak and unstable; no rescue.
10. **Present across multiple historical periods?** No — walk-forward folds show no consistent direction for either hypothesis.
11. **Does the live losing period resemble either pattern?** Not meaningfully — contextual only, sample far too small.
12. **Did either hypothesis satisfy VALIDATED?** No.
13. **Failed due to temporal instability?** Yes, for both — this is the specific, disclosed failure mode for both hypotheses.
14. **Failed due to insufficient sample?** Partially a contributing factor for H1 (only 2 of 6 cells adequately sampled) but the primary failure mode for both is direction instability, not raw sample size (both had adequate samples in their tested comparisons).
15. **Does Phase 50 justify designing a portfolio control?** No.
16. **Should any live strategy be modified?** No.
17. **Should any strategy risk be changed?** No.
18. **Should GBPJPY_AMR be changed?** No — explicitly out of scope and unsupported.
19. **Should JPY exposure be reduced?** No — unsupported by this phase's evidence.
20. **Should a concurrency limit be introduced?** No — unsupported; H2 explicitly rejected.
21. **Should another strategy search begin?** No — unchanged from Phase 39/45/46/48/49.
22. **Strongest surviving evidence?** None from this phase specifically — the strongest standing evidence remains Phase 48's parameter/cost robustness results and Phase 41's proportional-loss/multi-simultaneous-loser findings, both unaffected by this phase.
23. **Strongest rejected hypothesis?** Both are rejected at the same (D) tier; H2's discovery-to-validation sign flip on the full population is the more decisive single rejection, since it was the more directly falsifiable, higher-powered test.
24. **Largest remaining uncertainty?** Whether an alternative, not-yet-tested specification of either signal (continuous JPY measure, different concurrency threshold) would perform differently — explicitly untested here, per the no-threshold-mining rule.
25. **What should Phase 51 investigate?** Per the frozen decision tree (§31 of the task): **continue live observation; do not begin a new strategy search; do not design a portfolio control.** If Phase 51 investigates anything, it should be a different question entirely (e.g., accumulating further live evidence, per Phase 45's still-open forward-validation-window recommendation) rather than a third attempt at the same stress-signal question.
26. **Should Phase 51 investigate anything at all?** Optional, and if so, not a continuation of this specific line — per the decision tree's explicit "both fail → stop portfolio-control research for now."

### Final classification

**H1: D. REJECTED — NO CREDIBLE SIGNAL.**
**H2: D. REJECTED — NO CREDIBLE SIGNAL.**

Per the frozen decision tree: **BOTH HYPOTHESES FAILED → STOP PORTFOLIO-CONTROL RESEARCH FOR NOW. CONTINUE LIVE OBSERVATION. DO NOT BEGIN A NEW STRATEGY SEARCH.**

---

## Safety check confirmation

Preregistration committed (`1d55b16`) before results, unchanged after · six-strategy population unchanged · historical control unchanged · prediction timestamps verified (100% lookahead-safe, 0 failures) · no look-ahead · no future information used in any predictor · full eligible population used for both primary analyses · stress subset used only as secondary descriptive (H2) · H1 frozen · H2 frozen · primary hypotheses separated from exploratory interaction test · multiple testing addressed (`reports/phase50_multiple_testing.csv`) · temporal validation completed for both hypotheses · walk-forward completed (2 folds, sample-size-justified) · no threshold mining (median/4-threshold reused unchanged from prior phases, not searched) · no optimization · no strategy changes · no risk changes · no portfolio control · no deployment · live data kept separate throughout, labeled contextual only · Phase 44 not overturned · raw production 5ers export not committed.

---

*No live trading change authorized. Both hypotheses rejected. Per the frozen decision tree: stop portfolio-control research for now, continue live observation, do not begin a new strategy search.*
